Pattern I diseases may be treated with Jak inhibitors; pattern II diseases may be treated most specifically with IL-4Ra or IL-13 antibodies; and pattern III diseases may be treated with TNF-α, IL-17, or IL-23 inhibitors. Here, IL17A is linked to glycogen storage disease VI.